Affimed NV at Jefferies Healthcare Conference Transcript
Good morning, everyone. I'm Maury Raycroft, one of the biotech analysts at Jefferies, and it's with great pleasure that I'd like to welcome Adi Hoess, the CEO of Affimed. Thanks so much for joining us today, Adi.
Good morning, Maury. Thanks so much for the invitation. Happy to be here.
And today, we're going to do a fireside chat. So maybe for those who are new to the story, if you can provide a one-minute intro to Affimed.
Yeah. Affimed is a company that develops multi-specific antibodies. The intent is to activate the innate immune system, specifically NK cells and macrophages.
We are doing this in three ways: we use the innate cell engagers basically to power up, enhance the efficacy of natural killer cells; we use the innate cell engagers to not only activate innate immunity, but also adaptive immunity. So hence, we have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
